Biomea Fusion, Inc. (BMEA)
NASDAQ: BMEA · Real-Time Price · USD
1.910
-0.140 (-6.83%)
At close: Apr 21, 2026, 4:00 PM EDT
1.930
+0.020 (1.06%)
After-hours: Apr 21, 2026, 7:02 PM EDT
Biomea Fusion Employees
Biomea Fusion had 41 employees as of December 31, 2025. The number of employees decreased by 65 or -61.32% compared to the previous year.
Employees
41
Change
-65
Growth
-61.32%
Revenue / Employee
n/a
Profits / Employee
-$1,507,244
Market Cap
138.09M
Employees Chart
Employees History
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 41 | -65 | -61.32% |
| Sep 30, 2025 | 42 | -65 | -60.75% |
| Jun 30, 2025 | 63 | -49 | -43.75% |
| Mar 31, 2025 | 79 | -31 | -28.18% |
| Dec 31, 2024 | 106 | 3 | 2.91% |
| Sep 30, 2024 | 107 | 4 | 3.88% |
| Jun 30, 2024 | 112 | 18 | 19.15% |
| Mar 31, 2024 | 110 | 24 | 27.91% |
| Dec 31, 2023 | 103 | 20 | 24.10% |
| Sep 30, 2023 | 103 | 28 | 37.33% |
| Jun 30, 2023 | 94 | 22 | 30.56% |
| Mar 31, 2023 | 86 | 29 | 50.88% |
| Dec 31, 2022 | 83 | 32 | 62.75% |
| Sep 30, 2022 | 75 | 28 | 59.57% |
| Jun 30, 2022 | 72 | 52 | 260.00% |
| Mar 31, 2022 | 57 | 37 | 185.00% |
| Dec 31, 2021 | 51 | 39 | 325.00% |
| Sep 30, 2021 | 47 | 35 | 291.67% |
| Jun 30, 2021 | 20 | - | - |
| Mar 31, 2021 | 20 | - | - |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Humacyte | 184 |
| Innate Pharma | 174 |
| Fate Therapeutics | 161 |
| Molecular Partners AG | 134 |
| Connect Biopharma Holdings | 64 |
| Spero Therapeutics | 25 |
| Tiziana Life Sciences | 9 |
| Galectin Therapeutics | 9 |
BMEA News
- 21 days ago - Biomea Fusion Announces First Patient Dosed in Newly Initiated Phase II Programs Enrolling Type 2 Diabetes Patients Failing on Standard-of-Care Therapies - GlobeNewsWire
- 4 weeks ago - Biomea Fusion Reports Full Year 2025 Financial Results and Corporate Highlights - GlobeNewsWire
- 5 weeks ago - Biomea Fusion Presents Phase II COVALENT-111 Data in Type 2 Diabetes at the 19th International Conference on Advanced Technologies & Treatments for Diabetes 2026 - GlobeNewsWire
- 2 months ago - Biomea Fusion to Participate at Upcoming Investor Conferences - GlobeNewsWire
- 3 months ago - Biomea Fusion Enters 2026 Focused on Executing Key Icovamenib and BMF-650 Milestones - GlobeNewsWire
- 4 months ago - Biomea Fusion to Present at the 44th Annual J.P. Morgan Healthcare Conference - GlobeNewsWire
- 4 months ago - Biomea Fusion Announces KOL Presentation and Interview on Menin and Icovamenib at WCIRDC 2025 - GlobeNewsWire
- 4 months ago - Biomea Fusion Presents COVALENT-111 Study Results at the 23rd World Congress on Insulin Resistance, Diabetes & Cardiovascular Disease (WCIRDC) - GlobeNewsWire